Combined Use of a Novel Cardioplegic Formula With MPS® Versus Cardioplexol ® in Urgent Isolated CABG Using MiECC in Patients With Recent Acute Myocardial Infarction

University Hospital Basel

Status: Completed

Conditions: Coronary Artery Bypass Grafting (CABG); Cardioplegia Solution Adverse Reaction; Heart Attack

Treatments: Other: Cardioplexol; Other: Myocardial protection system (MPS)

Study type: Observational

Funder types: Other

Identifiers

NCT04309994

2019-02383 ch20Reuthebuch;

Details and patient eligibility

About

The goal of this study is to compare the two cardioplegia solutions (blood cardioplegia by means of MPS ® vs. Cardioplexol ®) regarding perioperative outcome and with special attention to cardiac markers in patients with a recent heart attack.

Enrollment: 307 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who underwent a CABG using MPS® or Cardioplexol ®
• Heart attack less than 7 days before surgery

Exclusion criteria

• use of other cardioplegia solution than Cardioplexol ® or MPS®
• other inventions than CABG
• explicit will of the patient that his data may not be used
• denied general consent

Trial design

307 participants in 2 patient groups

Experimental

Description:

bypass surgery with blood cardioplegia by means of MPS

Treatment:

Other: Myocardial protection system (MPS)

Active Comparator

Description:

bypass surgery with blood cardioplegia by means of Cardioplexol ®

Treatment:

Other: Cardioplexol